Drug intelligence / Profile preview

18F-LNC1019

Development stage: Preclinical
Lead developer: LNC Pharma
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

18F-LNC1019 is a diagnostic radiopharmaceutical developed by LNC Pharma for use in Positron Emission Tomography (PET) imaging. It is composed of a targeting ligand labeled with the radioisotope fluorine-18 (18F) that specifically binds to the Gastrin-Releasing Peptide Receptor (GRPR). GRPR is a G protein-coupled receptor that is frequently overexpressed in various malignancies, most notably in prostate and breast cancers. By targeting these receptors, 18F-LNC1019 enables the non-invasive visualization, characterization, and localization of GRPR-positive tumors, facilitating improved diagnosis and staging. The agent is currently in the preclinical stage of development.

Targets

GRPR (Gastrin-releasing peptide receptor)

Beyond the preview

Go deeper on 18F-LNC1019.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 18F-LNC1019.

Explore the full profile